Critical medications are in shortage due to COVID-19. In her latest blog post, AMCP CEO Susan A. Cantrell, RPh, CAE, discusses the prescription drug supply chain and highlights new COVID-19 resources for AMCP members.
These are trying times, especially for health care practitioners. Together, as managed care pharmacy professionals, we face challenges to patient care. AMCP CEO Susan A. Cantrell, RPh, CAE addresses these unique challenges in her latest blog post.
AMCP CEO Blog: AMCP has been working hard for several years to help members be ready when drugs are approved or off-label indications emerge. The first prong of our effort was to update the popular AMCP Format for Formulary Submissions.
AMCP CEO Blog: As a new decade dawns, AMCP is preparing for the twists and turns of an uncertain first year. With health care a top issue in this year’s presidential campaigns, drug pricing a favorite target, and biosimilar use poised to expand, seeing where this year will lead requires much more than “2020” vision.
Digital therapeutics: What are they, and where do they fit into pharmacy and medical benefits? Learn more in this blog post from AMCP CEO Susan A. Cantrell, RPh, CAE.
AMCP CEO Blog: With PA so often misunderstood, perhaps we need to do a better job of explaining this tool to the general public. For example, we might provide an example of how PAs are applied to opioids as additional safeguards to ensure their appropriate use. Or how a PA might be applied to botulinum toxin to ensure the prescription is for medical, rather than cosmetic, purposes.
By AMCP CEO Susan A. Cantrell, RPh, CAE • 11/13/19
AMCP CEO Blog: AMCP’s roughly 8,000 members work diligently every day to improve patient care through the optimized use of medicines. As an organization, we also take a leading role in developing improvements to the overall delivery of care, which is no easy task given the size and complexity of our health care system.